title: [A case of gastric cancer with multiple liver metastases resistant to TS-1 responding to chemotherapy with paclitaxel plus doxifluridine].
abstract: A 74-year-old man was revealed to have type 3 gastric cancer with synchronous multiple liver metastases. Despite treatment with TS-1 (120 mg/body), an increase in tumor size was demonstrated by computer tomography and endoscopy. We tried a course of a combination chemotherapy consisting of paclitaxel (PTX) plus doxifluridine (5'-DFUR ) to reduce the tumor. 5'-DFUR (600 mg/m(2)) was administered day 1 to 14 followed by 7 days'rest as one course. PTX (80 mg/m(2)) was infused on days 1 and 8. After 5 courses, the tumor markers decreased markedly, and computer tomography and endoscopy revealed remarkable tumor reduction which was thought to show a partial response. After 13 courses we discontinued this chemotherapy, so increase of the tumor marker was remarkable. This case suggests that PTX/5'-DFUR protocol is effective for clinical management of gastric cancer resistant to TS-1.
authors.affiliation: Second Dept. of Internal Medicine, Osaka Medical College.
authors.forename: Shin
authors.initials: S
authors.lastname: Kuwakado
authors.forename: Hiroya
authors.initials: H
authors.lastname: Takiuchi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Goto
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Kawabe
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Ohta
authors.forename: Takayuki
authors.initials: T
authors.lastname: Kii
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Tanaka
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Nishitani
authors.forename: Ken-ichi
authors.initials: K
authors.lastname: Katsu
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D004338:Drug Combinations; D019008:Drug Resistance, Neoplasm; D005467:Floxuridine / Q000008:administration & dosage; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000556:secondary*; D008297:Male; D010094:Oxonic Acid / Q000494:pharmacology*; D017239:Paclitaxel / Q000008:administration & dosage; D011725:Pyridines / Q000494:pharmacology*; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005641:Tegafur / Q000494:pharmacology*
chemical_list: D004338:Drug Combinations; D011725:Pyridines; D005467:Floxuridine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D017239:Paclitaxel; C025034:doxifluridine; D002166:Camptothecin